In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

When an undercover agent offered $3,500 for two 100 milligram vials of the drug, Kumar said, “At this price, we can’t deliver real or genuine Keytruda.” “Product will look like same but it ...

"During the first raid, 140 filled vials of spurious cancer injections of Opdyta, Keytruda, Dextrose, Fluconazole brands worth approximately Rs 1.75 crore were seized. Rs 50,000, $1000, three cap ...

Eli Lilly LLY launched a discounted single-dose vial version of its popular obesity ... evaluating blockbuster PD-L1 inhibitor Keytruda for a type of lung cancer and skin cancer, respectively.

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with ...